Oncology

Researchers conducted a systematic review of randomized trials to determine the efficacy of ketamine for patients with cancer.

Research from ESMO 2024 focused on the relationship between survival outcomes and medication adherence.

Cologuard Plus is approved for adults aged 45 years and older who are at average risk for the disease.

This approval offers an additional treatment option for a disease that can commonly return.

A study found there were 216 active supportive care clinical trials and that industry sponsors rarely provided funding.

Patients who completed electronic patient-reported outcome measures said they made them feel more involved in their care and better supported.

The #MyCRChistory campaign encourages the public to share their family history of colorectal cancer.

The FDA approved imetelstat (Rytelo) in June 2024.

A cohort study was conducted to address the association between patients with cannabis-related disorders and their risk of developing head and neck cancer.

The technology from Diakonos Oncology initiates a natural immune response that targets and eliminates cancer cells by activating cytotoxic TH1 cell signaling pathways.

Afami-cel is the first new treatment for synovial sarcoma in more than 10 years, ending a long-standing therapeutic gap.

A pilot study presented at the American Diabetes Association 84th Scientific Sessions showed that CGM technology could produce reliable results without complications in children with leukemia/lymphoma at risk for hyperglycemia.

Four abstracts presented at ASCO 2024 delved into cannabis and pain management, potential medication interactions, and symptom mitigation, in patients with cancer.

In 2 abstracts presented at ASCO 2024, researchers addressed the use of GLP-1s for weight loss and to reduce cardiovascular outcomes in women with breast cancer.

In abstracts presented at the 2024 American Society of Clinical Oncology’s annual meeting, researchers addressed the association between heart failure and multiple types of cancers.

Researchers addressed the use of cannabis to treat cancer symptoms in rural and urban areas, as well as patients’ comfortability discussing it with their providers.

Researchers addressed patients’ preferences for the delivery method of educational cancer resources as well as the demographics that were influenced to read materials or not.

Posters presented at ENDO 2024 investigated excessive weight gain in breast cancer survivors and how high insulin levels impact outcomes for Black women with an aggressive form of the disease.

Study results were promising, but larger studies are needed.

Roche's self-collection kit allows women to screen for cervical cancer at home, offering an alternative to a visit to a health care provider and promoting early detection of the disease.

The approval of Lisocabtagene maraleucel (Breyanzi; liso-cel) was based on data from the TRANSCEND-NHL-001 study, in which the therapy showed rapid and durable response rates.

Research exploring the growing role of artificial intelligence (AI) in health care sheds a light on the potential of the technology to improve skin cancer detection and awareness among patients and health care professionals.

Research presented at Digestive Disease Week suggests that including omega-3 rich foods, or omega-3 supplements, into a healthy diet could offer additional protection against colorectal cancer alongside regular screening.

Amgen’s Tarlatamab-dlle (Imdelltra) is the first and only approved DLL3-targeting bispecific T-cell engager therapy for the aggressive form of lung cancer.

Warm weather means one thing: People are eager to be outdoors. Although sun protection is paramount, sunscreen options can be daunting. How can pharmacists help?

For Melanoma and Skin Cancer Awareness Month, Drug Topics sat down with Colleen McCabe, PharmD, BCOP, to glean clinical insights into promoting skin cancer awareness in the community pharmacy.

WGc-043 is the first and only vaccine approved for this use.

A siloed approach to care can worsen patient outcomes, but collaboration between one health system specialty pharmacy and a manufacturer led to better patient care.

“I think in those situations where you can use the lower cost of the drug, you should, because it's going to help the overall societal perspective. That begins to break down, though, when that low-cost drug is the one that you're losing money on,” said Scott Soefje in a Q&A on balancing cost and margin at a site of care.

A Q&A with Karen Fancher, PharmD, associate professor of pharmacy practice at Duquesne University School of Pharmacy, on applying ethical principles to manage complex situations in oncology pharmacy.